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LIST OF ABBREVIATIONS 
 
Ach, acetylcholine; 2-AG, 2-arachidonoylglycerol; Ang II, angiotensin II; AT1R, type 1 angiotensin 
receptor; BK, bradykinin; CB1R, type 1 cannabinoid receptor; DAG, diacylglycerol; DAGL, 
diacylglycerol lipase; EC, endocannabinoid; ERK, extracellular signal-regulated kinase; HPLC, high 
performance liquid chromatography; KO, knockout; LAD, left anterior descending; LNA, Nω-nitro-L-
arginine; MAG, monoacylglycerol; NO, nitric oxide; qRT-PCR, quantitative real-time PCR; PLC, 
phospholipase C; THC, Δ9-tetrahydro-cannabinol; THL, tetrahydrolipstatin; SNP, sodium-nitroprusside; 
VSMC, vascular smooth muscle cell 
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INTRODUCTION 
Hemodynamic resistance of intramural coronary arterioles with diameters below 200 µm 
determines local ventricular flow. Such vessels have a substantial spontaneous/myogenic tone which is 
kept reduced by metabolic factors from surrounding ventricular tissue, beta adrenergic effects, endothelial 
NO and also by vasodilatory prostanoids produced in the wall. Compared to resting coronary vascular 
flow, during heavy physical exercise and also in hypoxia a 4-5 times increase in cardiac blood flow 
(“coronary vasomotion”) can be achieved 1-7.  
 It has been revealed, that exogenous tetrahydro-cannabinol  (THC)
8
,  anandamide, 2-
arachidonoilglycerol (2-AG)
9-10
 ,  different natural and  synthetic agonists of the CB1R (e.g. WIN55212)
11-
14
 cause  substantial vasodilation in several vascular beds,  such as in coronary arteries 
9-11
, cerebral 
arteries
11
, the mesenteric vascular bed
8 
 and  in the aorta
14
. Several hemodynamically and clinically 
important resistance arteries also responded to cannabinoids 
8,15
. Most vasodilatory and hypotensive 
actions of cannabinoids seem to involve the CB1R receptors 
11,15,16.
 
Endocannabinoids are produced in the wall of different vessels and by their vasodilatory actions 
they contribute to local vascular control
15-22
.  However, the extent of this contribution can be much 
different in different vascular areas
18-24
. Exogenous cannabinoids increased coronary flow in isolated 
rodent hearts
25
, dilated larger coronary arteries
9,10,17,26
 and even cardioprotective and antiischemic 
effects
27-29 
have been attributed to them. In an earlier work from our laboratory
16
, we have demonstrated 
that continuous production of endocannabinoids (mostly 2-arachnoidylglycerol, 2-AG) in the wall of 
skeletal muscle resistance arterioles maintained a reduced spontaneous and agonist induced tone via 
vascular CB1 receptors.  Pharmacological control of coronary resistance arteries might be much different 
from that of resistance arteries in other vascular areas
3
 and may even differ from larger coronary vessels
5
.  
Myogenic contraction and tone of resistance-sized arteries involves different agonist-induced and cellular 
mechanisms 
30
.  
Taking into consideration the unique clinical significance of the coronary vascular system and the 
specific features of coronary resistance artery control it is of utmost importance to study whether 
  4 
endocannabinoid-mediated vasodilatory mechanisms do exist in coronary resistance arteries and to what 
extent they are able to modulate the myogenic and agonist induced coronary vascular tone. 
 
MATERIALS AND METHODS 
 
Animals 
Male Wistar rats were used (250-350g, Charles River Laboratories-Semmelweis University, 
Budapest). All animals were anaesthetized with pentobarbital sodium (Euthasol, ASTfarma 50 mg/kg 
intraperitoneally) and an extra dose (appr. 10 mg/kg) was additionally given, if necessary. Anesthetized 
animals were sacrificed by fast bleeding. The investigation conforms to the Guide for the Care and Use of 
Laboratory Animals   (NIH, 8th edition, 2011) as well as National legal and institutional guidelines for 
animal care. They were approved by the Animal Care Committee of the Semmelweis University, 
Budapest and by Hungarian authorities (No. 263/003/2008 and No. 001/2139-4/2012). 
 
Chemicals 
Angiotensin II, bradykinin (BK), WIN55212 (a CB1R agonist), Nω-nitro-L-arginine (an inhibitor 
of nitric oxide synthase) and tetrahydrolipstatin (THL, a diacylglycerol lipase inhibitor) were purchased 
from Sigma-Aldrich (St. Louis, MO, US). The neutral CB1R antagonist O2050,  the inverse CB1R agonist 
AM251 were purchased from Tocris Bioscience (Elliswille, MI, US). All other salts and chemicals were 
purchased from Sigma. 
 
Immunohistochemistry  
Hearts from rats and mice were fixed in 4% paraformaldehyde and placed in 10 and 20% sucrose 
solutions (15–18 hrs each) for cryoprotection. The tissues were quickly frozen on dry ice, embedding, 
sectioning and staining were executed as described 
22,31
. Immunostaining was performed with CB1R 
primary antibody (Cayman Chemicals, Ann Arbor, MI, overnight). The development of slides was made 
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using the biotin extravidin ABC method (Vector Labs, Burlington, CA). Diaminobenzidine (DAB) was 
used for visualization
22,31
. Antibody specificity was confirmed preparing aortic slides of wild and CB1R -
/- knockout mice.  
 
Western blots 
Microdissected samples were washed twice in ice cold PBS solution (composition in mM, NaCl 
137, KCl 2.7, Na2HPO4 10.1, KH2PO4 1.8, pH 7.4).  They were homogenized in glass tubes and lysed in 
SDS lysis buffer containing 10 % merkapto-ethanol and protease inhibitor cocktails (Sigma-Aldrich). In 
the lysis buffer samples were sonicated, boiled and centrifuged. Proteins from tissue samples were 
separated with SDS-polyacrylamide gel electrophoresis and were blotted onto the PVDF membrane. 
Membranes were treated with antibodies against CB1R (Cayman Chemicals) and beta-actin (Sigma-
Aldrich) followed by the treatment with HRP-conjugated secondary antibodies. Visualization was made 
with SuperSignal West Pico reagent (Promega, Madison, WI) and results were quantitatively evaluated 
with densitometry.  
 
RNA extraction and real-time PCR  
Vascular tissues were removed by fast and careful microscopic dissection for RNA extraction
16
. 
In anesthesia, the chest was opened, the heart removed. Intramural coronary arterioles branching from the 
left anterior descendent coronary artery were isolated. Vessels were placed in cold sterile phosphate 
buffer solution (PBS as above). Total RNA was extracted (RNeasy mini kit, Qiagen) and reverse 
transcription was carried out according to the manufacturer’s instructions (Fermentas, Ontario, Canada). 
Real-time PCR assays were performed on LightCycler 480 (Roche Applied Science, Indianapolis, IN) 
with the SYBR Green method. Primers were designed and synthesized by Sigma-Aldrich. Cycling 
conditions were: 10 min preincubation at 95 ºC, 45-50 cycles of 95 ºC 10 sec, 62 ºC 5 sec and 72 ºC 15 
sec. Fluorescence data including melting curves were obtained. For normalization, the glyceraldehyde-3-
phosphate dehydrogenase (gapdh) housekeeping gene was used (ENSRNOG00000004253). Efficiency 
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for each primer pair was determined by
 
using serial dilutions of the PCR product. Fold ratios of gene 
expression were calculated as follows: 
 
Ratio=E 
ΔCt target gene
 / E 
ΔCt GAPDH
 
 
Ct was calculated by the second derivative method using LightCycler 480 Software. ΔCt is the difference 
in Ct values obtained between the reference and tested samples. Relative messenger RNA levels of 
cannabinoid receptor type 1 (Cnr1) were calculated (ENSRNOG00000008223). Primers were for Cnr1: 
forward primer GGACTCAGACTGCCTGCACA, reverse primer ACAAAAGCAGCAGGCTCACA and 
for gapdh: forward primer CCTGCACCACCAACTGCTTAG, reverse primer 
CAGTCTTCTGAGTGGCAGTGATG. Tissue gene expression levels were plotted against gapdh 
expression level. 
 
Isolation of rat coronary resistance arteries for video microarteriography 
During anaesthesia of rats, the chest was quickly opened, the heart removed and placed into cold 
normal Krebs-Ringer  (nKR) solution which contained in mM, NaCl 110, KCl 5, CaCl2 2,5, MgSO4 1,0,  
KH2PO4 1,0, NaHCO3 24 and glucose, 10 (pH 7.4). Intramural coronary arterioles branching from the left 
anterior descending (LAD) coronary artery were isolated by careful microdissection as described 
previously 
5,32,33
. Distal segments close to the apex with approximately 100-150 μm of inner diameter 
were prepared. One segment was prepared and measured from each animal. The segment was placed in a 
tissue bath filled with Krebs solution. It was cannulated at both ends with microcannulas, extended to its 
in situ length in the glass bottomed tissue bath of a pressure microarteriography chamber (Experimetria, 
Budapest). Clotted blood was washed out at low perfusion pressure, and then one of the cannulas was 
closed. Utilizing a pressure-servo syringe reservoir system (Living Systems, Burlington, VT, US) 
arterioles were pressurized in a no-flow condition. Vessels were checked for leaks by the stability of the 
inlet pressure when the servo function was turned off. Vessels with observable leaks were discarded. The 
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temperature of the chamber was maintained at 37 
o
C, bubbled with 21 % O2 and 5 % CO2 , balanced with 
N2, the pH was kept at 7.4. A continuous superfusion of the bath was applied at a rate of  2.5 mL/min. 
The cannulated vessel was visualized by video-microscopy and the inner diameter was measured on 
frozen images (Leica inverted microscope, Leica DFC 320 digital camera, LeicaQWin software)
5,6,16,32
. 
Calibration was made with a micrometer etalon (Wilde, Heerbrugg, Switzerland). Intraluminal pressure 
was calibrated with a mercury manometer.  
 
Experimental protocols of isolated vessel studies 
Following a 60-min equilibration period, at 50 mmHg intraluminal pressure in nKR solution, 
pharmacological responses of the arterial segments were tested according to the specific protocols. 
Agonists were administered in a dose-dependent manner into the chamber and steady-state diameter was 
recorded for each dose or in a single (submaximal) dose. 10-min washout periods were applied between 
drugs. Inhibitors were applied for at least 10 minutes prior to and during agonist administration. Each 
inhibitor was applied in separate experimental series, either the pressurized segments were in spontaneous 
myogenic contraction or their contraction was enhanced with Ang II.  In coronary vessels, Ang II is 
suitable to produce precontraction, since it produces a stable contraction without observable 
desensitization response in contrast to other type of vessels like gracilis arterioles and aorta
16,22
. After Ang 
II precontraction (1 µM),  SNP (1 µM) was applied to test endothelium-independent vasodilation.  
Endothelial relaxation was tested by bradykinin (100 nM), which is an appropriate endothelium-
dependent vasodilator in coronary resistance arteries of rats
5
. The experiments were terminated by 
obtaining passive (relaxed) vascular diameter in calcium-free Krebs solution. 
In the first group of experiments (n=14), rat coronary arterioles were subjected to elevated doses 
of agonists, Ang II (0.1 nM-10 µM), WIN55212 (0.1 nM-1 µM), SNP (0.1 nM-10 µM) and BK (0.1 µM) 
with  the CB1R neutral antagonist O2050 (1 μM)  or only its vehicle being present in the bath. Since 
WIN55212 is lipid-soluble, it was applied prior to and after CB1R antagonist in separate vessel segments. 
In the second group (n=5), concentration-response to Ang II was obtained before and during the 
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administration of the DAG lipase inhibitor tetrahidrolypstatin (1 μM) or its vehicle. In a third 
experimental set (n=6), the effect of CB1 receptor antagonist (inverse agonist) AM251 (1 μM) (or its 
vehicle) on the tone of coronary arterioles and on WIN55212- and SNP-induced vasodilations were 
tested. In a fifth set of experiments (n=5), the effect of Nω-nitro-L-arginine (an inhibitor of nitric oxide 
synthase, 50 μM) was applied 20 minutes prior and during the administration of CB1R agonist WIN55212 
(1 μM) or the endothelium-dependent agonist BK (0.1 µM)  in order to test the role of NO in the CB1R-
mediated coronary functions. 
 
Statistical analysis  
 
Data are presented as means±SEM. Vascular tone was calculated as percent change from passive 
diameter. Changes in vascular diameter were also calculated as percent change from control value. For 
paired data we used the Student’s t-test, for multiple comparisons one-way and two-way ANOVAs were 
applied (SigmaStat). Concentration-response curves without and with inhibitors present in the solution 
were compared using the four parameter logistic function (SigmaPlot). Relative gene expression levels 
were plotted against reference control (gapdh). P<0.05 was considered significant for each comparisons. 
 
RESULTS 
 
Molecular and functional evidence of the expression and presence of CB1Rs in intramural coronary 
resistance arteries 
 CB1R protein is present in the wall of these rodent microvessels as it has been demonstrated by 
immunohistochemistry of ventricular tissue.  Immunostaining appeared in the wall of intramural coronary 
arterioles (Fig. 1A.). Western blots also proved the expression of the CB1R protein in the wall of rat small 
coronary arteries isolated by microdissection (Fig. 1B.). In addition, messenger RNA for CB1 receptors 
was also detected  by qRT-PCR in amounts similar to those found in rat aortic tissue (Fig. 1C.). Segments 
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in myogenic contraction relaxed in response to the CB1R agonist WIN 55212 (1 µM). Further, this 
relaxation could be inhibited by the specific blockers O2050 (1 µM), and AM251 (1 µM). These CB1R 
antagonists, however, did not affect either endothelium independent (SNP, 1 µM) or endothelium 
dependent (BK, 0.1 µM) relaxations (tested on Ang II precontracted segments, Fig. 1D-E.).   
 
Evidence of  existence of an intrinsic CB1R activation during spontaneous myogenic contraction 
Coronary arteries when pressurized, exhibit a substantial spontaneous, myogenic tone in 
oxygenized nKR solution. This, with all probability mimics the in vivo situation 
5,32,33
. We tested whether 
a basal endocannabinoid release affects the spontaneous tone in these vessels. Vascular diameter of our 
segments during spontaneous contraction (following an equilibration period) was  138.7±6.6 µm (inner 
diameter) corresponding to 20.1±2.9 % (n=15)  myogenic tone (compared with relaxed controls).  
 
The neutral CB1 receptor antagonist (O2050, 1 µM) moderately  (2.6±1.7 %, n.s.), the inverse 
CB1R agonist AM251 (1 µM) significantly increased coronary myogenic tone (6.0±1.0 %, p<0.05). The 
DAG lipase enzyme inhibitor THL (1 µM) effectively increased basal coronary tone (11.2±3.9 % 
contraction, p<0.05). This effect was additive with the similar effect of AM251: a substantial diameter 
reduction of 24.6±5.3%   (p<0.05) was reached when both antagonists were applied together (Fig. 2.). 
Products of the enzyme DAG lipase must be the main endocannabinoids in this tissue.  These experiments 
indirectly prove that spontaneous myogenic tone of these vessels is kept under continuous control by 
endogenously produced 2-AG.  This control can be considered fairly effective as the myogenic 
contraction of these vessels practically doubles if 2-AG synthesis and endocannabinoid  action on CB1Rs 
are  both inhibited at the same time.  
 
Effect of exogenous cannabinoid on coronary arterial tone 
 Adding angiotensin II to the bath further contracts coronary arteries, this contraction is added to 
the myogenic one. The specific CB1R agonist WIN55212 very effectively relaxed coronary arteriole 
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segments precontracted with close-to-maximal concentrations of Ang II (1 µM). The concentration-
dependent vasodilation by the CB1R agonist WIN 55212 is shown on Fig. 3A, which is effectively 
inhibited by the CB1R antagonist O2050. This record proves that agonist induced contraction of coronary 
resistance arterioles can be inhibited by exogenous stimulation of the cannabinoid receptors.  However, 
the concentration-dependent vasodilation by the NO donor sodium nitroprusside (SNP) was not affected 
by these CB1R antagonists (Fig. 3B and D).  Fig. 3. and Fig 1D demonstrate an interesting fact:  
WIN55212, a  CB1R agonist is an almost as effective a coronary vasodilator as the well-known NO donor 
SNP is. 
 
Agonist induced contraction goes on with parallel CB1R activation 
Ang II elevated coronary arteriole tone in a dose-dependent manner, at maximal concentrations  
inducing about a 20% further reduction of diameter of segments in spontaneous contraction. This effect 
reached a maximum level around 10 µM of Ang II concentration. Inhibition of CB1 receptors by O2050, 
significantly enhanced Ang II-induced contractions of coronary arterioles  (significant over 100 nM Ang 
II,  p<0.05, Figure 4).  The four parameter logistic analysis has shown that there was not significant 
change in logEC50% values for Ang II contraction (-7.36±0.19 vs. -7.54±0.21 without and with the 
antagonist, respectively, n.s.), while maximum contraction values significantly elevated (17.8±1.2 vs. 
29.1±2.9%, p<0.05). These observations prove that during agonist induced contraction, a continuous and 
stimulated endocannabinoid production is present in the wall which modulates contraction due to its 
effect on CB1Rs. 
 
Effect of inhibition of DAG lipase enzyme on the agonist-induced response 
The DAG lipase blocker THL also augmented Ang II-induced contractile response in the 
coronaries (Figure 5, p<0.05 at 1 nM-100 nM of Ang II). Based on this observation, it is highly probable  
that 2-AG is the endocannabinoid whose production is elevated by Ang II in this vascular preparation and 
the co-stimulation of CB1Rs produced limits then Ang II contraction
22
.  
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Role of endothelial nitric oxide in CB1R induced coronary vasodilation 
The coronary dilatory effect of the CB1R agonist Win 55212 on Ang II precontracted segments 
was partially suspended by the NO synthase blocker Nω-nitro-L-arginine (50 µM), suggesting a partially 
NO mediated effect (Fig 6., p<0.05). By comparison, the dilatory effect of bradykinin, an endothelial 
coronary vasodilator, was fully diminished by the same concentration of LNA (p<0.001). 
 
 
DISCUSSION 
 
Substantial modulator effect found both in myogenic and in agonist induced contraction 
 Our observations demonstrated the existence and a substantial functional role of CB1Rs in rodent 
intramural coronary arterioles, vessels that basically determine local ventricular flow. The presence of 
CB1R protein (with immune-histochemistry and Western blot, Fig 1A. and 1B.) and of its mRNA (Fig. 
1C.) have been first proven in this vessel-type. We have also proved that endocannabinoids acting on such 
receptors play an important role in forming myogenic and agonist induced tone of these vessels. The 
specific CB1R agonist WIN55212 induced a substantial concentration-dependent vasodilation (Figs. 3A. 
and 3C.)  which was prevented by the CB1R neutral antagonist O2050  (Fig. 3A.) and by the inverse 
agonist AM251 (Fig. 3C.). AM251 and the DAG lipase enzyme inhibitor THL substantially increased 
coronary arteriole myogenic tone (Fig. 2.).   Ang II induced tone was augmented both by O2050 and THL 
(Figs.4. and 5.). We have a sound foundation to declare that a DAG lipase product endocannabinoid, with 
all probability   2-AG is continuously synthesized in the wall of these vessels, and the amount produced is 
enhanced by Ang II. Both the spontaneous myogenic and Ang II-induced contractions are attenuated by 
its effect. As neither SNP nor BK relaxations were effected by CB1R antagonists (Fig. 3B. and D.), we 
can conclude that simply altering the contractile state of a coronary arteriole segment will not 
automatically alter its endocannabinoid production.  
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Coronary cannabinoid-mediated relaxation 
 We have found a significant CB1R-mediated vasorelaxation in rat coronary arterioles (Fig. 3A, 3C.). 
Our findings are in accord with an earlier publication by White
9
 who found that isolated rings prepared 
from the left anterior descendent coronary artery of the rat  (not a resistance sized artery) and 
precontracted with 5-HT,  dilated in response to exogenous anandamide.  This dilation could be inhibited 
by the CB1R blocker SR14176A. It is interesting to note that he has found the more specific CB1R 
blocker AM251 less effective. There seems to be some contradiction also with the observations by Mair
26
.  
On main coronary artery branches of the rat, precontracted with U46619 (a thromboxane agonist), he has 
found that relaxation occurred through CB2Rs due to activation of the ERK1/2 pathway and vasodilatory 
prostanoids.  Our opinion is that tissue composition and function of larger coronary arteries viable for 
wire myographic studies can be substantially different from the real resistance vessels studied by us using 
the pressure arteriography technique.  
 
Coronary endocannabinoid production and relaxation 
  Endocannabinoid production has been detected in different vascular beds and also in heart
15-22
. 
Several types of cells of different vascular tissues can be sources of endocannabinoids: endothelial cells, 
smooth muscle cells, perivascular neurons, platelets, leukocytes, monocytes, macrophages etc.
18,34-36
. 
Endogenous release of 2-AG has been observed from human vascular endothelial cells.  The 2-AG 
released was supposed to be an intrinsic vasomodulator
37
. In bovine coronary arteries, metacholine 
stimulates endothelial 2-AG release through PLC and DAGL activation and serves as an intermediate for 
vasodilatory eicosanoid release
34
.  Not only endothelial cells but also vascular smooth muscle cells can 
release 2-AG
22
. We have found previously that Ang II-stimulated 2-AG-release from vascular smooth 
muscle cells has been attenuated by the inhibition of DAG lipase and augmented by monoacylglycerol 
(MAG) lipase inhibition
22
. In conformity with the vascular production of 2-AG, we have also found that 
inhibition of DAG lipase augmented, while inhibition of MAG lipase attenuated vasoconstriction of the 
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aorta.  This indicates the role of locally released 2-AG in the control of vascular tone in this vessel
22
. 
Similarly, a previous observation found that 2-AG production in rat aorta was enhanced by carbachol
38
.  
The contribution of the endocannabinoid mechanism to lumen control in these important vascular 
segments is substantial, we have a good reason to suppose  a physiological impact.  We have found here 
that inhibition of DAGL, the enzyme responsible for the production of a substantial part of tissue 
endocannabinoids, augmented coronary resistance artery tone by around 10% even without adding any 
stimulants (Fig. 5.). The double inhibition of the endocannabinoid effect (CB1R +DAGL inhibition) 
induces 24.6±5.3% contraction, that practically doubles the approximately 20% spontaneous myogenic 
tone (Fig. 2.). We can conclude that similarly to endogenous prostanoids and NO
22
, a continuous 
production of vasodilatory endocannabinoids in the resistance artery wall counterbalances the myogenic 
tone in coronary resistance arteries. The concentration-dependent Ang II-induced contraction of these 
segments has also been accompanied by a stepwise elevation of the moderating effects of endogenous 
cannabinoids. Both the CB1R antagonist O2050 and the DAG lipase blocker THL augmented Ang II-
induced contraction when compared with contraction without the antagonist (Figs. 4. and 5.). This makes 
it highly probable, that “basal” endocannabinoid release (and its vasorelaxation effect) is increasing with 
increasing concentrations of the contracting agonist. According to a previous observation from our 
laboratory, in nonvascular cells, co-expressing the AT1- and CB1 receptors, Ang II-induced stimulation of 
AT1R via the activation of PLC and DAG-production led to the transactivation of CB1 receptors by 
endocannabinoid release
38,39
. The Ang II-induced CB1 receptor activity was inhibited by DAGL inhibitor 
suggesting, that 2-AG production from DAG plays an important  role in the mediation of this action
40
. 
Similarly, our previous observation on skeletal muscle arterioles indicated that inhibition of CB1 receptors 
augmented Ang II-induced vasoconstriction by increasing both efficacy and the potency of the Ang II-
induced responses
16
. 
Considering the mechanism of this relaxing effect, our present studies on coronary arterioles 
suggest a mechanism analogous that found in skeletal muscle arterioles. The AT1R, Gq, PLC, DAG 
pathway produces a substrate for the DAG lipase, the 2-AG produced co-activates CB1Rs in the 
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neighborhood, inducing, by a not fully identified yet action, relaxation, limiting the contraction exerted.  
How does the co-activation of CB1Rs relax these vessels? K
+ 
channel-mediated cell 
hyperpolarization
9,10,17,41
, depression of Ca
2+
 influx
41
,
42
, modulation of endogenous prostanoid 
production
9,10,26,35
, activation of Gi/o or other G proteins
3,9,40
 are the mechanisms suggested in the literature 
by different authors.  
 The role of endothelium and endothelium-mediated nitric oxide in the cannabinoid-induced 
vasodilatory response seems to be different in different vascular territories.  Previously, in gracilis 
arterioles we found that WIN55212-induced vasodilation was not attenuated by the blocker of NO 
synthase nitro-L-arginine, while it  effectively inhibited acetylcholine-induced vasodilation
16
.  Also, we 
have found that the removal of endothelium did not change the augmented vasoconstrictor effect induced 
by the CB1R blocker O2050 in gracilis vessels. Sources of vascular endocannabinoids can be  
heterogenous: 2-AG production has been detected both from endothelial cells and from vascular smooth 
muscle cells
22,35,37,38
.  These observations are in good accordance with our present observations on 
coronary resistance vessels,  inhibition of NO synthesis caused a partial (by approx. 50%) attenuation of 
the CB1R agonist WIN55212-induced vasodilation (Fig. 6.).  
 
Potential physiological role 
We can remark here that such intrinsic “braking” feed-backs frequently occur in complex  
physiological control networks.  In case of the coronary resistance artery control mechanisms, the 
endothelial NO and endogenous prostanoid production, stimulated by agonists,  can be mentioned. We 
and other laboratories have also found earlier that myogenic and agonist-induced tone of coronary 
resistance arteries are fine-tuned by altered NO and vasoactive prostanoid production occurring in the 
wall of these vessels
3,6,7
  Now, we can add to this a similar new mechanism: endogenous cannabinoid 
production. One can theorize on the potential physiological benefits: Full contraction closing the lumen 
can be prevented by them or, certain contractile effects can be neutralized. Anyway, they yield a more 
  15 
complex and more versatile lumen control mechanism, which is able to respond to diverse physiological 
needs in a more diverse manner.  
 
Conclusion 
 
Our studies have proven the existence of the CB1R protein, its mRNA and also its functional 
relevance to induce substantial vasodilation in the wall of intramural coronary resistance arteries, vessels 
that basically determine ventricular local flow. Further, we provide clear evidence that a vasorelaxant  
endocannabinoid system is present in these vessels, which substantially contributes to the physiologically 
important lumen controlling mechanisms here through vascular CB1 receptors.  This mechanism is active 
both during spontaneous myogenic contraction and also in Ang II-induced contraction. We suggest, that 
to the known physiological mechanisms that reduce the substantial spontaneous/myogenic tone of 
coronary resistance vessels (metabolic factors, beta adrenergic stimuli, vasodilatory prostanoids and 
endothelial NO) the endogenous cannabinoids should be added.  
 
ACKNOWLEDGEMENTS 
  The authors are grateful to Dr. Gábor Turu, Dr. Zsuzsanna E. Tóth (Semmelweis University, 
Budapest), Dr. Andreas Zimmer (University of Bonn) and Dr. Istvan Katona (Institute of Exp. Med. of 
the Hungarian Academy of Sciences, Budapest) for helpful discussion of the manuscript. The authors are 
grateful to Ildikó Oravecz, Judit Rácz, Ilona Oláh and Anikó Schulcz for their expert assistances. The 
authors declare that there is no conflict of interest that would prejudice the impartiality of the present 
work.  
 
 
GRANTS 
  16 
This work was supported by grants from the Hungarian National Science Foundation (OTKA NK-
100883, NK-72661) and the National Development Agency, Hungary (TÁMOP 4.2.1.B-09/1/KMR-
2010-0001). 
 
DISCLOSURES, CONFLICTS OF INTERESTS 
None is declared. 
 
AUTHOR CONTRIBUTIONS 
M.Sz. and L.H.: conception and design of research. M.Sz. and G.L.N. performed experiments. M.Sz., 
G.L.N. and E.S-K. performed analysis. M.Sz. and G.L.N. interpreted results of experiments. M.Sz. and 
E.S-K. prepared figures. M.Sz. drafted manuscript. L. H. edited and revised manuscript. L. H., M.Sz., 
G.L.N. and E.S-K. approved final version of manuscript. 
 
 
REFERENCES 
 
1. Kuo L, Davis MJ, Chilian WM. Myogenic activity in isolated subepicardial and subendocardial 
coronary arterioles. Am J Physiol 1988;255:H1558-H1562. 
 
2. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise.  Physiol Res 2008;88:1009-
1086. 
 
 
3. Duncker DJ, Koller A, Merkus D, Canty JMJr. Regulation of coronary blood flow in health and 
ischemic heart disease. Progr Cardiovasc Dis 2015;57:409-422. 
 
  17 
4. Laughlin MH, Bowles DK, Duncker DJ. The coronary circulation in exercise training. Am J Physiol 
Heart Circ Physiol 2012;302:H10-H23. 
 
5.  Szekeres M, Dezsi L, Nadasy GL, Kaley G,  Koller A. Pharmacologic inhomogeneity between the 
reactivity of intramural coronary arteries and arterioles. J Cardiovasc Pharmacol  2001;38: 584-592. 
 
6. Szekeres M, Nadasy GL, Kaley G, and Koller A. Nitric oxide and prostaglandins modulate pressure-
induced myogenic responses of intramural coronary arterioles. J Cardiovasc Pharmacol 2004;43: 242-
249. 
 
7. Toda N, Toda H. Coronary hemodynamic regulation by nitric oxide in experimental animals: Recent 
advances. Eur J Pharmacol  2011;667:41-49. 
 
8.  O'Sullivan SE, Kendall DA, and Randall MD. The effects of Delta9-tetrahydrocannabinol in rat 
mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol  
2005;145: 514-526. 
 
9. White R, Ho WSV, Bottrill FE, Ford WR, and Hiley CR. Mechanisms of anandamide-induced 
vasorelaxation in rat isolated coronary arteries. Br J Pharmacol  2001;134: 921-929. 
 
10. Grainger J and Boachie-Ansah G. Anandamide-induced relaxation of sheep coronary arteries: the role 
of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol  
2011;134: 1003-1012. 
 
11. Wagner JA, Jarai Z, Batkai S, and Kunos G. Hemodynamic effects of cannabinoids: coronary and 
cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol  2001; 423: 203-210. 
  18 
 
12. Randall MD, Harris D, Kendall DA, and Ralevic V. Cardiovascular effects of cannabinoids. 
Pharmacol Ther  2002;95: 191-202. 
 
13. Randall MD, Kendall DA, and O'Sullivan S. The complexities of the cardiovascular actions of 
cannabinoids. Br J Pharmacol  2004;142: 20-26. 
 
14.  Dannert MT, Alsasua A, Herradon E, Martin MI, and Lopez-Miranda V. Vasorelaxant effect of Win 
55,212-2 in rat aorta: new mechanisms involved. Vascul Pharmacol 2007;46: 16-23. 
 
15. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, 
Rudd MA, Bukoski RD, and Kunos G. Endocannabinoids acting at cannabinoid-1 receptors regulate 
cardiovascular function in hypertension. Circulation 2004;110: 1996-2002. 
 
16. Szekeres M, Nadasy GL, Turu G, Soltesz-Katona E, Toth ZE, Balla A, Catt KJ, and Hunyady L. 
Angiotensin II Induces Vascular Endocannabinoid Release, Which Attenuates Its Vasoconstrictor Effect 
via CB1 Cannabinoid Receptors. J Biol Chem 287: 31540-31550, 2012. 
 
17. Randall MD and Kendall DA. Involvement of a cannabinoid in endothelium-derived hyperpolarizing 
factor-mediated coronary vasorelaxation. Eur J Pharmacol 1997; 335: 205-209. 
 
18. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther 2000;294: 27-32. 
 
19. Hiley CR. Endocannabinoids and the heart. J Cardiovasc Pharmacol  2009;53: 267-276. 
 
  19 
20. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, and Kunos G. Modulation of the 
endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension  
2008;52: 601-607. 
 
21. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, Kunos G, and Ertl G. 
Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll 
Cardiol  2001;38: 2048-2054. 
 
22. Szekeres M, Nadasy GL, Turu G, Soltesz-Katona E, Benyo Z, Offermanns S, Ruisanchez E, Szabo E, 
Takats Z, Batkai S, Toth ZE, and Hunyady L. Endocannabinoid-mediated modulation of Gq/11 protein-
coupled receptor signaling-induced vasoconstriction and hypertension. Mol Cell Endocrinol  2015;403: 
46-56. 
 
23. Stanley C, O’Sullivan SE. Vascular targets for cannabinoids: animal and human studies.  Review.  Br 
J Pharmacol 2014;171:1361-1378. 
 
24. O’Sullivan SE. Endocannabinoids and the cardiovascular system in health and disease (Review) 
Handbook Exptl Pharmacol  2015;231:393-422. 
 
25. Wagner JA, Abesser M, Karcher J, Laser M, Kunos G. Coronary vasodilator effects of endogenous 
cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol 
2005;46:348-355. 
 
26. Mair KM, Robinson E, Kane KA, Pyne S, Brett RR, Pyne NJ, and Kennedy S. Interaction between 
anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br J 
Pharmacol  2010;161: 176-192. 
  20 
 
27. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, and Bonner TI. Increased mortality, 
hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 
1999;96: 5780-5785. 
 
28. Bouchard JF, Lepicier P, and Lamontagne D. Contribution of endocannabinoids in the endothelial 
protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 2003;72: 1859-1870. 
 
29. Wagner JA, Abesser M, Harvey-White J, and Ertl G. 2-Arachidonylglycerol acting on CB1 
cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J 
Cardiovasc Pharmacol  2006;47: 650-655. 
 
30. Kim EC, Choi SK, Lim M, Yeon SI, Lee YH. Role of endogenous ENaC and TRP channels 
in the myogenic response of rat posterior cerebral arteries. PLOS One 2013;8(12)e84194):1-9. 
 
31. Toth ZE, Mezey E. Simultaneous visualization of multiple antigens with tyramide signal 
amplification using antibodies from the same species. J Histochem Cytochem 2007;55: 545-554. 
 
32. Nadasy GL, Szekeres M, Dezsi L, Varbiro S, Szekacs B, and Monos E. Preparation of intramural 
small coronary artery and arteriole segments and resistance artery networks from the rat heart for 
microarteriography and for in situ perfusion video mapping. Microvasc Res 2001;61: 282-286. 
 
33.Szekeres M, Nadasy GL, Dezsi L, Orosz M, Tôkés A, Monos E: Segmental differences in geometric, 
elastic and contractile characteristics of small intramural coronary arteries  J Vasc Res 1998; 35:332-344.  
 
  21 
34. Gauthier KM, Baewer DV, Hittner S, Hillard CJ, Nithipatikom K, Reddy DS, Falck JR, and Campbell 
WB. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in 
bovine coronary arteries. Am J Physiol Heart Circ Physiol 2005;288: H1344-1351. 
 
35. Lipez-Miranda V, Herradon E, and Martin MI. Vasorelaxation caused by cannabinoids: mechanisms 
in different vascular beds. Curr Vasc Pharmacol 2008;6: 335-346. 
 
36. Pacher P, Batkai S, and Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp 
Pharmacol 2005; 599-625. 
 
37. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, and Waku K. Detection of an 
endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor 
mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem 
Biophys Res Commun 1998;243: 838-843. 
 
38. Mechoulam R, Fride E, Ben-Shabat S, Meiri U, and Horowitz M. Carbachol, an 
acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a 
hypotensive endocannabinoid. Eur J Pharmacol 1998;362: R1-R3. 
 
39. Turu G, Simon A, Gyombolai P, Szidonya L, Bagdy G, Lenkei Z, and Hunyady L. The role 
of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid 
CB1 receptor activity. J Biol Chem  2007;282: 7753-7757. 
 
  22 
40. Turu G, Varnai P, Gyombolai P, Szidonya L, Offertaler L, Bagdy G, Kunos G, and Hunyady 
L. Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other 
Gq/11 protein-coupled receptors. J Biol Chem   2009;284: 16914-16921. 
 
41. Turu G and Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 
2010;44: 75-85. 
 
42. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, and Harder DR. Cannabinoid CB1 
receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J 
Physiol 1999;276: H2085-2093. 
  23 
 
Fig. 1. Molecular and functional evidence of the presence of the CB1R in the intramural coronary 
resistance arterioles of the rat.  A.  Immunohistochemical localization in histological sections of 
ventricular tissue pieces containing the arterioles.  Stainings of CB1Rs are indicated by arrows.  Bar 
shows 100 µm. B. Western blot of CB1R protein from homogenates of microsurgically isolated resistance 
artery specimens.  C. Expression of mRNA for CB1R in coronary resistance artery specimens (CA) and in 
the aorta (AO) of rats as determined by qRT-PCR  (n=5). Expression fold vs. gapdh houskeeping gene is 
plotted. D-E.  Relaxation in response to CB1R agonist (WIN55212,  1μM), inhibition  of relaxation by the 
specific CB1R antagonists O2050 and AM251 (1μM) of Ang II-precontracted coronary artery segments.  
SNP-induced (1μM, an endothelium independent vasodilator, n=11) and bradykinin-induced  (BK, 
0.1μM, an endothelium dependent coronary vasodilator) vasodilations were not affected by CB1R 
antagonists (segments  precontracted with 1μM Ang II,  n=8). Mean ± SEM values are shown. *, P<0.05 
between control and inhibitor-treated values. 
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Fig. 2. Intrinsic CB1R activity keeps myogenic tone reduced. The type 1 cannabinoid receptor (CB1R)-
antagonists O2050 (a neutral antagonist, 1μM) and  AM251 (an inverse agonist, 1μM) and also the 
diacylglycerol (DAG) lipase-inhibitor tetrahydrolypstatin (THL, 1μM, inhibits the production of 2-AG) 
substantially increase the spontaneous tone of pressurized rat coronary arteries (n= 5 or 6 for each group). 
Mean ± SEM values are shown. *, P<0.05 between control and inhibitor-treated values. 
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Fig. 3. CB1R-mediated modulation of agonist-induced contraction.  A.  Concentration dependent 
dilation of Ang II (1μM) precontracted coronary arteriole segments in response to different concentrations 
of the  CB1R agonist WIN55212. The relaxation is almost completely inhibited in the presence of the 
specific CB1R blocker O2050 (1μM).  B. For comparison, concentration-dependent vasodilation effect of 
NO donor sodium nitroprusside on coronary artery segments, which was not affected by the CB1R 
antagonist treatment.  C and D. Similar responses were detected with the CB1R inverse agonist AM251 
(1μM).  
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Fig. 4. CB1R-mediated modulation of agonist-induced contraction. Enhancement of concentration 
dependent Ang II contraction in the presence of the cannabinoid receptor (CB1R) antagonist O2050 
(1μM) in the tissue bath (n= 10 and 8). Mean ± SEM values are shown. *, P <0.05 between control and 
inhibitor-treated values.   
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Fig. 5.  Identification of the vasodilatory effect of a diacylglycerol lipase product. Enhancement of 
concentration-dependent Ang II-induced contraction in the presence of the DAG lipase blocker 
tetrahydrolipstatin (THL, 1μM) in the tissue bath (n= 6 and 5).  Mean ± SEM values are shown. *, P 
<0.05 between control and inhibitor-treated values. 
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Fig. 6. Endothelial component of CB1-R vasodilation. The CB1R agonist WIN55212 (1μM)-induced 
vasodilation was partially blocked by the presence of Nω-nitro-L-arginine in the bath (50 µM, n= 5). For 
comparison, the full inhibition of BK induced relaxation by LNA is demonstrated to the right. Mean ± 
SEM values are shown. *, P <0.05 and *** P <0.01 between control and inhibitor-treated values.   
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